The Behçet’s Disease Treatment Market Focuses On Therapies For Managing This Rare Autoimmune Disorder, Characterized By Blood Vessel Inflammation, Which Can Lead To Symptoms Affecting The Eyes, Mouth, Skin, And Genitals. Treatments Typically Aim At Reducing Inflammation And Relieving Symptoms, Using Corticosteroids, Immunosuppressive Agents, And Biologics. Key Players In This Market Include Novartis, Abbvie, Celgene, And Ucb Pharma, Who Focus On Enhancing Biologic Therapies Such As Tnf Inhibitors And Il Inhibitors, Which Offer Targeted Relief With Fewer Side Effects. Recent Developments Include Research Into Advanced Biologics And The Repositioning Of Existing Immunomodulatory Drugs To Target Complex Behçet’s Symptoms. Geographically, North America And Europe Hold Substantial Market Shares Due To Strong Healthcare Infrastructure And Awareness Programs, While Asia-Pacific Is Witnessing Rising Demand With Increasing Awareness And Access To Advanced Therapies. Market Growth Is Supported By Ongoing Clinical Trials And The Need For Effective, Tailored Treatments For Patients With Varying Symptom Profiles.